Oct 21, 2026 earnings call — New CEO outlines strategy; solid Q3 results
Raised full-year adjusted diluted net EPS guidance to $8.57-$8.62.
Revenue $6.6B (est $6.6B) · EPS $2.11 (est $1.92)
Key quotes
"Execute better and more entrepreneurially, show up together as Danaher for our customers, and connect our capabilities where we can create greater value."
"We recently announced our first AI-powered autonomous lab."
"Orders grew mid-teens in the quarter, with particular strength in both upstream consumables as well as reagents."
Analyst Q&A 7
preserve strengths, evolve priorities
Q (Doug Schenkel · UBS): The analyst asked how the new CEO balances Danaher's legacy playbook of operational excellence with the need to change. He also asked which single priority will have the greatest near-term impact and which metrics investors should watch.
A: Management said she will preserve what makes Danaher great while focusing on the priorities for today's company, including becoming more connected across businesses. The near-term top priority is accelerating profitable growth and unambiguous share gain; investors should watch higher core growth and profitable core growth as the report card.
"Step one is really prioritizing aligning our teams around accelerated profitable growth and unambiguous share gain as the report card, and that's what our investors should be looking for." — Julie Sawyer Montgomery (CEO)
bioprocessing growth and M&A focus
Q (Vijay Kumar · Evercore): The analyst asked whether bioprocessing should grow high single digits or low double digits in fiscal 2027 given strong orders and reshoring, and also asked about capital deployment and whether recent deals signal a med-tech tilt.
A: Matt said 2026 expectations for bioprocessing remain mid-single digit core growth, with mid-teens order growth and an expectation of improvement in 2027; he views bioprocessing long term as a high single digit growth business. Julie said M&A remains the bias for capital allocation and they will pursue strategically compounding deals under robust investment criteria; she does not view Masimo as a med-tech tilt but as strategically compounding with Diagnostics.
"M&A remains our bias for capital allocation as we think it is the best way to compound returns over the long term, and we are going to continue to look for strategically compounding M&A." — Julie Sawyer Montgomery (CEO)
2027 guide and respiratory outlook
Q (Tycho Peterson · Jefferies): The analyst asked why the company is keeping a 4%-5% ex-respiratory starting point instead of accelerating the guide, and asked why respiratory was reduced again and whether $1.5 billion is the right endemic level.
A: Management said 4%-5% core growth ex-respiratory is a reasonable starting point based on recent quarters and they will finish their Q4 planning and give a quantitative outlook in January. On respiratory, they are planning for $1.5 billion this year and consider that the right starting point for next year; they described that as a down-the-middle flu season and said it's too early to call a fuller uptick until ILI exceeds 3%.
"We are planning for $1.5 billion in respiratory this year, and I think that's also the right starting point for next year as well." — Julie Sawyer Montgomery (CEO)
AI strategy and autonomous lab
Q (Jack Meehan · Operon): The analyst asked how AI affects Danaher and how the company is deploying AI with its Danaher Business System (DBS). He also asked about recent AI-related announcements with NVIDIA and the autonomous lab.
A: Management said AI-driven drug discovery is a significant long-term opportunity and Danaher is well positioned because it has the needed building blocks: instruments, consumables, automation, software, and scale. They described an autonomous lab that closes the design-make-test loop (showing 8x faster reagent discovery and 10x productivity) and noted collaborations with NVIDIA and Anthropic to integrate compute, models, and connectivity across instruments.
"We believe that Danaher is uniquely positioned to help shape this market, frankly, because we have all of the building blocks." — Julie Sawyer Montgomery (CEO)
sales execution changes and M&A process
Q (Scott Davis · Melius): The analyst asked what concrete steps will drive faster commercial execution—changes to compensation, people, or processes—and how M&A process will change to improve hit rate while keeping deal flow.
A: Management said they are enforcing a simple commercial standard condition in DBS with clear expectations for sales teams and are even testing AI to coach and inspect sales performance. For connected selling they will align incentives so no one's pay is hurt (even willing to double-pay incentives) and they will not freeze M&A; instead they will focus on strategically compounding deals with robust processes and teams.
"When we first started doing this in Diagnostics, one of our rules is when we have a solutions group team go out and talk to customers, no one's incentives are ever hurt." — Julie Sawyer Montgomery (CEO)
Masimo, bioprocessing orders, reshoring timing
Q (Casey Woodring · JPMorgan): The analyst asked how Masimo is trending and how it should contribute next year, and asked for detail on bioprocessing equipment order strength and how reshoring orders could impact 2027.
A: Julie said Masimo is off to a strong start, delivering high single digits in Q3 and year-to-date with integration progressing and commercial synergies building. Matt said bioprocessing orders were mid-teens led by upstream consumables and resins, with equipment orders up strongly in the double-digit range, and Julie said reshoring currently shows modest brownfield activity but larger greenfield projects are mostly planning-stage and expected to be a 2028-plus P&L event, though it could be a billion-dollar U.S. opportunity over several years.
"We do think this is a strong opportunity ultimately for the business, and it could be a billion-dollar market opportunity in the U.S." — Julie Sawyer Montgomery (CEO)
Life Sciences recovery and demand
Q (Evie Koslosky · Goldman Sachs): The analyst asked where recovery stands across Life Sciences end markets—academic, biotech (including emerging biotech), industrial, and semis—and which areas could accelerate spending next year.
A: Management said Life Sciences grew 4.5% in Q3 and has beaten internal expectations for three quarters, with end markets steadily improving: large pharma and biopharma robust, biotech funding showing improvement, and academic demand still below historic levels but modestly better. They also noted strength in clinical and applied markets and early demand for AI-driven workflow solutions showing up in automation, with Danaher positioned to offer easier integration across instruments.
"You saw here in Q3, we grew 4.5% and finished above our expectations, driven by the improving end markets and the traction on some recent commercial initiatives, as well as some new product launches." — Julie Sawyer Montgomery (CEO)